Evaluating the Impact of Dienogest on Quality of Life in Turkish Patients with Endometriosis: A Clinical Study

Purpose This study aimed to evaluate the effectiveness of dienogest in alleviating the negative effects associated with endometriosis in Turkish patients. The impact of the treatment on health-related quality of life (HRQoL) was assessed using the validated Turkish version of the Endometriosis Health Profile-30 (EHP-30) questionnaire. Methods A total of 119 patients with a confirmed diagnosis of endometrioma characterized by a unilocular cyst with homogeneous ground-glass echogenicity were included in this study, conducted at a tertiary care center. All participants were prescribed or already have been prescribed a continuous regimen of 2 mg/day dienogest for symptom control. Each patient completed the core section of the EHP-30 questionnaire twice: before treatment initiation and after a defined treatment period. Results A significant improvement was observed in total EHP-30 scores (from 96.92 to 52.03, p < .001). Notable improvements were also found in the pain (p < .001), self-image (p < .001), and emotional well-being (p < .001) subdomains. Changes in EHP-30 scores were not found to be significantly correlated with treatment duration, reduction in endometrioma size, or changes in CA125 levels. Conclusion Dienogest significantly improves quality of life even with short-term use and stands out as an effective treatment option for endometriosis.